Proxy Results (Form 8-K)

Item 5.07. Submission of Matters to a Vote of Security Holders.

Estrella Immunopharma, Inc. (the "Company") held its Combined 2025/2026 Annual Meeting of Stockholders (the "Annual Meeting") on June 29, 2026, at 10:00 a.m. Eastern Time by means of remote communication, in a virtual-only format, via live audio webcast.

As of the close of business on May 20, 2026, the record date for the Annual Meeting, there were 43,034,228 shares of the Company's common stock outstanding and entitled to vote. Holders of 30,351,608 shares of common stock were present or represented by proxy at the Annual Meeting, constituting approximately 70.5% of the shares of common stock outstanding and entitled to vote and a quorum for the transaction of business.

One proposal was submitted to a vote of the Company's stockholders at the Annual Meeting. The proposal is described in detail in the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on May 27, 2026. The final voting results are set forth below.

Proposal 1- Ratification of Appointment of Independent Registered Public Accounting Firm

The Company's stockholders ratified the appointment of Macias Gini & O'Connell LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results were as follows:

There were no broker non-votes with respect to Proposal 1. Based on the final voting results, Proposal 1 was approved.